Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

PubMed

Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.

PMID : 30227064 · 2016

L, i, q, i, n, g, , W, a, n, g, ;, , H, a, n, g, , Z, h, e, n, g, ;, , X, i, a, o, h, o, n, g, , R, e, n, ;, , H, e, , S, u, n

RevueTherapeutic innovation & regulatory science
Année2016
PMID30227064

Résumé

The US Food and Drug Administration (FDA) is responsible for protecting public health. Issuance of a warning letter is the FDA's principal means of achieving prompt voluntary compliance with regulations. The objective of this study is to analyze the trends of warning letters issued to medical products about current good manufacturing practices (CGMP) violations during 2007-2014, with a secondary purpose of providing suggestions to manufacturers on how to avoid warning letters. Warning letters we

Source officielle

Voir sur PubMed →

Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.

↑